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ABSTRACT
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline 
mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed 
with ovarian cancer associated with this mutation.
METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov 
decision process from the perspective of the National Health System. The strategies compared 
reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual 
care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost 
per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner.
RESULTS: The study showed increments for effectiveness and for costs when performing 
genetic testing and adopting prophylactic measures for family members. The incremental 
cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered 
lower than the study’s cost-effectiveness threshold (R$7,543.50).
CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the 
national situation. Studies in various other countries have reached similar conclusions. One 
possible ramification of this research might the need to perform a budgetary-impact analysis 
of making the program one of the country’s health policies.
DESCRIPTORS: Ovarian Neoplasms, diagnosis. Genes, BRCA1. Genes, BRCA2. Early Detection 
of Cancer, economics. Cost-Effectiveness Evaluation.
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INTRODUCTION
According to data provided by the National Cancer Institute, around 6,150 new cases of 
ovarian cancer are recorded every year in Brazil1. Although this neoplasm only makes up 
a small proportion of the cases of malignancies diagnosed in the country, at the moment, 
it has the second highest mortality rate for all gynecological tumors2.
One of the main risk factors associated with the development of this neoplasm is genetic 
predisposition3,4. Hereditary breast and ovarian cancer syndrome, which is related to 
mutations in the BRCA1 and BRCA2 genes, is an important cause of ovarian carcinoma. It 
is present in 15% to 19% of all cases5,6. Germline BRCA1/2 mutation testing is not currently 
funded by the National Health System, and the estimated prevalence rate of this mutation 
in Brazil is similar to several other studies.
Because of the strong association between ovarian carcinoma and germline mutation, 
different professional bodies have recommended counselling and genetic testing for any 
woman who develops a malignant tumor7,8. The benefit of testing is that the mutation 
significantly increases the risk of a second primary cancer and frequently affects the choice 
of treatment9. Performing a diagnostic exam also allows family members who carry the 
germline mutation to be identified, so they can be offered risk-reduction therapy9. The 
current recommendation to manage risk in women who are carriers of a mutation in the 
BRCA1 and BRCA2 genes consists of offering risk-reducing salpingo-oophoerectomy and 
bilateral prophylactic mastectomy7,10.
Therefore, the objective of this study was to analyze the cost effectiveness of the program for 
diagnosing the germline mutation in the BRCA1/2 genes and of the preventative strategies 
offered to the relatives of patients who develop ovarian cancer.
METHODS
General Characteristics of the Study
The study analyzed the cost effectiveness of the program that diagnoses germline mutations 
in the BRCA1/2 genes and of preventative strategies offered to the relatives of patients with 
ovarian cancer associated with this mutation. Germline mutation was already confirmed 
in these ovarian cancer patients, being either BRCA1 or BRCA2.
The perspective from the National Health System in the federal domain (Ministry of Health) 
was selected. The model of analysis for the decision adopted corresponded with the Markov 
model. This type of model was chosen because of the longer horizontal follow-up period and 
because of the need to simulate the transition between different states of health across fixed 
intervals of time. Figure 1 shows a consolidated version of the model proposed for this study.
The alternatives compared herein consisted of performing genetic tests on first-degree 
female family members of patients who have ovarian cancer and the germline mutation 
or the usual care currently proposed. In the group of family members who, hypothetically, 
underwent genetic testing, the simulation strategy consisted of offering risk-reducing 
salpingo-oophorectomy and bilateral prophylactic mastectomy when the germline mutation 
was present in the BRCA1/2 genes. When mastectomy was refused, we simulated annual 
follow-up by complementary exams (magnetic resonance imaging of the breasts and a 
bilateral mammogram). The model did not adopt conducts aiming the early diagnosis 
of ovarian cancer, in situations where the salpingo-oophorectomy was refused, since the 
tracking methods currently available are not effective for this purpose11. No prophylactic 
conduct was simulated for family members without the germline mutation in the BRCA1/2 
genes. For each trajectory described, we simulated the possibility of subsequent development 
of malignant neoplasms of the breasts and ovaries.
3Cost effectiveness of the BRCA1/2 program Ramos MCA et al.
https://doi.org/10.11606/S1518-8787.2018052000643
In the group that, hypothetically, did not undergo genetic testing, annual follow-up with 
magnetic resonance imaging of the breasts and a bilateral mammogram were simulated 
when the algorithm of risk for the germline mutation was equal to or greater than 10%. No 
Figure 1. Markov model for strategies involving relatives of patients with ovarian cancer.
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additional conduct was simulated when the algorithm of risk for mutation was lower than 
10%. In addition, for each of the trajectories described, we represented the possibility of 
subsequent development of breast and ovarian cancers.
The model’s temporal horizon extended from 30 to 70 years of age, with annual cycles to 
evaluate any transition in states and the development of cancer. Neither the age at which 
BRCA1/2 testing was done nor the age at which risk-reducing salpingo-oophorectomy and 
bilateral prophylactic mastectomy were performed varied (30 years-old).
We adopted the following premises for this model: no family member had previously 
undergone genetic testing nor had a prior diagnosis of malignant breast and ovarian 
neoplasms, and family members who were not carriers of mutations in the BRCA1/2 genes 
had the same risk as the general population for the development of malignant breast and 
ovarian neoplasms.
Definition of the Estimates of Effectiveness
The definition of effectiveness was cancer cases prevented, discounted at 5%.
An umbrella research project provided demographic data, results related to the application 
of the algorithms of risk, and information about the prevalence of germline mutations in 
patients diagnosed with ovarian cancer in Brazil6,12.
Information related to the possible adherence to preventative strategies, penetrance of the 
germline mutations in the BRCA1/2 genes, and the reduction of risk in the development of 
neoplasm by prophylactic surgery were obtained based on research in the PubMed database. 
In addition, we performed an electronic search for studies that did an economic evaluation 
of germline mutation in the BRCA1 and BRCA2 genes.
Definition of the Estimates of Costs
The costs of genetic testing were defined based on commercial proposals received from 
manufacturers or local distributors. The monetary value in dollars or euros was converted 
into the Brazilian currency, based on the average quotations for the year 2014 (R$2.35 and 
R$3.12, respectively)13. The estimations involved measuring the costs for next-generation 
sequencing and for multiplex ligation-dependent probe amplification.
The sums involved in the program to reduce the risk of malignant neoplasm were defined 
by a panel composed of specialists and the hospital’s clinical guidelines. The definition of 
costs involved the macro-costing method. The unit values corresponded to those described 
in the Table of Procedures, Medications and Ortheses, Prostheses, and Special Materials 
for the National Health System14. This reference point was chosen because it corresponds 
to the main component of health financing in Brazil, incorporating different geographic 
situations and health providers. Moreover, adopting a single pattern might help alleviate 
eventual distortions and discrepancies in the Table’s values.
All data for the costs was presented in Brazilian Real for 2014. The annual discount rate for 
the costs adopted in the study was 5%, in line with the Guideline Methods for Economic 
Evaluation published by the Ministry of Health15.
Demonstration of the Results and Sensitivity Analysis
Estimation and demonstration of the results of the economic evaluation were performed 
using the TreeAge Pro sotfware, version 2017 (TreeAge Software Inc. Williamstown, 
Massachusetts). For each strategy compared, the anticipated costs and respective 
effectiveness were presented. The ratio of incremental cost effectiveness, estimated based on 
the mathematical ratio between the increment of costs and the increment of effectiveness, 
was expressed in terms of cost per case prevented. As a comparative reference, we used the 
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cost-effectiveness thresholds developed by the Center for Health Economics at the University 
of York (R$7,543.50 to R$23,786.70)16.
We performed the sensitivity analysis in a deterministic and univariate manner. This analysis 
consisted of an individual evaluation of the main parameters of this study, while the others 
remained constant. The analysis was presented in graph form as a Tornado Diagram. The 
references for variability resulted in values for the 95% confidence interval for the parameters.
RESULTS
The proportion of patients diagnosed with ovarian cancer and the germline mutation found 
in the project was 17% with the BRCA1 gene and 2% with the BRCA2 gene6. Given that the 
transmission of the mutation in autosomal dominant inheritance is 50%, the proportion 
of family members was estimated at 45% for carriers of the BRCA1 gene mutation, 5% for 
carriers of the BRCA2 gene mutation, and 50% for those without the mutation.
Penetrance of the mutations involving the BRCA1 gene and breast cancer is more 
expressive than that for the BRCA2 gene and ovarian cancer17. In fact, the probability 
of developing breast cancer is more prominent in the presence of a germline mutation 
in BRCA1 (57%) than in BRCA2 (49%)17. A similar situation occurs, though less often, for 
ovarian cancer, in which the probability of developing cancer is higher among carriers of 
a germline mutation in the BRCA1 gene (40%) than among carriers of a germline mutation 
in the BRCA2 gene (18%)17.
The parameters for adherence to risk-reducing surgeries and the impact of performing them 
on the future development of breast and ovarian cancer have also been determined17–20.
Table 1. Probabilities used in the decision model.
Description Estimate Range Reference
Probability of mutation in BRCA1 gene 0.45 - Maistro et al.6 (2016)
Probability of mutation in BRCA2 gene 0.05 - Maistro et al.6 (2016)
Probability of adherence to bilateral prophylactic mastectomy 0.57 0.47–0.66 Chen et al.17 (2007) 
Probability of adherence to risk reduction salpingo-oophorectomy 0.49 0.40–0.57 Chen et al.17 (2007)
Probability of developing breast cancer in the absence of mutation in BRCA1/2 genes 0.06 0.03–0.08 Ferlay et al.30 (2013)
Probability of developing ovarian cancer in BRCA1 mutation carrier, in the absence of 
prophylactic surgery
0.40 0.35–0.46 Chen et al.17 (2007)
Probability of developing ovarian cancer in BRCA2 mutation carrier, in the absence of 
prophylactic surgery
0.18 0.13–0.23 Chen et al.17 (2007)
Probability of developing ovarian cancer in the absence of mutation in BRCA1/2 genes 0.006 0.005–0.01 Ferlay et al.30 (2013)
Probability of adherence to bilateral prophylactic mastectomy 0.18 0.16–0.20 Metcalfe et al.18 (2008)
Probability of adherence to risk reduction salpingo-oophorectomy 0.57 0.55–0.59 Metcalfe et al.18 (2008)
Probability of developing breast cancer in BRCA1 mutation carrier, after mastectomy 0.04 0.03–0.05
De Felice et al.19 (2015); Chen 
et al.17 (2007)
Probability of developing breast cancer in BRCA2 mutation carrier, after mastectomy 0.03 0.03–0.04
De Felice et al.19 (2015); Chen 
et al.17 (2007)
Probability of developing breast cancer in BRCA1 mutation carrier, after 
salpingo-oophorectomy
0.28 0.23–0.32
Rebbeck et al.20 (2009); Chen 
et al.17 (2007) 
Probability of developing breast cancer in BRCA2 mutation carrier, after 
salpingo-oophorectomy
0.24 0.20–0.28
Rebbeck et al.20 (2009); Chen 
et al.17 (2007)
Probability of developing breast cancer in BRCA1 mutation carrier, after mastectomy and 
salpingo-oophorectomy
0.02 0.01–0.03
De Felice et al.19 (2015); Rebbeck 
et al.20 (2009); Chen et al.17 (2007)
Probability of developing breast cancer in BRCA2 mutation carrier, after mastectomy and 
salpingo-oophorectomy
0.02 0.01–0.02
De Felice et al.19 (2015); Rebbeck 
et al.20 (2009); Chen et al.17 (2007)
Probability of developing ovarian cancer in BRCA1 mutation carrier, after 
salpingo-oophorectomy
0.08 0.07–0.10
Rebbeck et al.20 (2009); Chen 
et al.17 (2007)
Probability of developing ovarian cancer in BRCA2 mutation carrier, after 
salpingo-oophorectomy
0.04 0.03–0.05
Rebbeck et al.20 (2009); Chen 
et al.17 (2007)
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The costs involved next-generation sequencing and the evaluation of multiplex 
ligation-dependent probe amplification totaling R$683.61. The risk-reducing surgical 
procedures had the billing charges listed in the Table of Procedures, Medications, Ortheses, 
Prostheses and Special Materials of the National Health System.
The cost of screening for breast cancer in patients with a germline mutation in the BRCA1/2 
genes totaled R$333.75 per year. For family members who did not have genetic testing, 
Figure 2. Tornado Diagram related to incremental cost-effectiveness ratio.
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Probability of ovarian cancer in BRCA1 mutation carrier, after salpingo-oophorectomy
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Probability of breast cancer in BRCA2 mutation carrier, after magnetic resonance and mammography
Probability of breast cancer in the absence of mutation in BRCA1/2 genes
Probability of ovarian cancer in BRCA2 mutation carrier, in the absence of screening
Probability of ovarian cancer in BRCA2 mutation carrier, after salpingo-oophorectomy
Table 2. Cost estimates used in the decision model.
Description Cost
Genetic counseling consultations R$200.00
Next generation sequencing and evaluation for large genomic rearrangements R$683.61
Bilateral prophylactic mastectomy R$3,158.04
Risk-reducing salpingo-oophorectomy R$542.46
Breast magnetic resonance imaging and bilateral mammography, in the presence of 
BRCA1/2 germline mutation and refusal to mastectomy (annual cost)
R$333.75
Breast magnetic resonance imaging and bilateral mammography, in the presence of risk 
algorithm ≥ 10% (annual cost) R$80.10
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annual expenditure was represented by the product of the probability of being at high risk 
for the mutation (24%) and the cost of screening (R$333.75), yielding a result of R$80.10.
Thus, based on the definition of the estimates of effectiveness and of the costs, we proceeded 
to develop Tables 1 and 2, which consolidate the parameters used in the model.
The program to diagnose germline mutation and preventative strategies involving family 
members of patients with ovarian cancer proved to be cost effective, compared with the 
lowest threshold of cost effectiveness adopted (R$7,543.50). In fact, although the program 
had a higher cost (R$1,241.22 versus R$78.96), its effectiveness was better (R$16.13 versus 
R$14.85) than the strategy involving no genetic testing. Thus, the ratio of incremental cost 
effectiveness was estimated at R$908.59 per case of cancer prevented.
The Tornado Diagram showed that the parameters with the greatest influence on the model’s 
results, during the univariate sensitivity analysis, were penetrance of the mutation in the 
BRCA1 gene and the impact of not performing prophylactic surgeries. Individual variation 
in these parameters did not change the incremental cost-effectiveness ratio in an expressive 
way, so that the technology remained cost effective. Figure 2 illustrates this situation.
Finally, the number of family members eligible for the strategy, per year, was estimated at 
2,045 individuals (6,150 cases of ovarian cancer per year multiplied by 19% of these cases 
related to BRCA1/2 germline mutation multiplied by 3.5 first-degree female relatives per 
patient with ovarian cancer, multiplied by 50% probability of transmission of the mutation).
DISCUSSION
The program for diagnosing a germline mutation in the BRCA1/2 genes and for preventative 
strategies, aimed at family members of patients diagnosed with ovarian cancer, proved to be 
a cost-effective alternative, from the perspective of the National Health System. It is a strategy 
located in quadrant I of the cost-effectiveness plan, consisting of a more effective and more 
costly intervention21. In this case, the comparison between the incremental cost-effectiveness 
ratio and the cost-effectiveness threshold proved favorable to the adoption of the program.
In addition, the cost per case of cancer prevented (R$908.59) was lower than the amounts 
typically spent on treating the cancer. In fact, data from our cohort of patients with 
ovarian cancer had more expressive billing figures (Table 3), over a period of five years of 
tracking, with palliative chemotherapy as the main driver of costs. In this respect, adopting 
prophylactic strategies for carriers of a germline mutation in the BRCA1/2 genes could reduce 
costs and need for palliation in cases of tumor progression.
The indication of genetic testing for patients with ovarian cancer and the subsequent 
adoption of preventative strategies for family members carrying the germline mutation was 
also the motive behind a North American study22. This study concluded that testing all cases 
of ovarian cancer could be prohibitively expensive in comparison with the cost-effectiveness 
threshold adopted in the United States22. On the other hand, restricting the test to situations 
of prior personal history of breast cancer, family history of malignant breast and ovarian 
neoplasms or Ashkenazi Jewish background showed cost-effective results22.
Table 3. Costs of ovarian cancer treatment by year.
Year Mean cost 95%CI
1st R$12,958.48 R$11,504.42–R$14,412.54
2nd R$3,960.10 R$2,783.99–R$5,136.22
3rd R$4,860.90 R$3,597.02–R$6,124.78
4th R$4,167.97 R$2,934.69–R$5,401.24
5th R$3,508.02 R$1,993.53–R$5,022.51
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In this context, different studies emphasize evaluation, at the level of population, of preventative 
strategies for people with a higher risk of having a germline mutation23–26 One of these publications, 
analyzing conduct for individuals with a predictive algorithm of risk for the BRCA1/2 mutation 
equal to or higher than 10%, proved inconclusive regarding the use of technology, since the costs 
and effects of the alternatives adopted are similar to not having genetic testing23.
Three different publications analyzed a specific group at high risk for the germline mutation 
in the BRCA1/2 genes: Ashkenazi Jews24–26. The studies assessed specific sequencing for 
founder mutations. Thus, Rubinstein et al.25 concluded that the screening program for 
the germline mutation increased survival at an acceptable cost. One limitation of this 
study, which focused entirely on ovarian cancer, was the lack of strategies to reduce 
the risk of breast cancer25. Manchanda et al.24, in turn, verified that a population-based 
screening strategy could save money and promote greater effectiveness by performing 
genetic tests only on people with a family history of malignant neoplasm. Finally, Grann 
et al.26 showed the superiority of combined surgery over exclusive mastectomy, exclusive 
salpingo-oophorectomy and the usual practice of watching and waiting for this population.
Other studies have assessed preventative strategies for individuals who carry the germline 
mutation in the BRCA1 and BRCA2 genes27–29. Thus, the study conducted by Anderson 
et al.29 showed a favorable incremental cost-effectiveness for the combination of bilateral 
prophylactic mastectomy and risk-reducing salpingo-oophorectomy. Another publication, 
which assessed preventative strategies for carriers of a mutation in the BRCA1 gene, reached 
a similar conclusion, pointing out that salpingo-oophorectomy, with or without bilateral 
prophylactic mastectomy, should be cost effective28. Similarly, Grann et al.27 suggested 
that, for carriers of a germline mutation in the BRCA1/2 genes, prophylactic surgery is cost 
effective in comparison with chemoprevention and screening.
Therefore, the overall verdict of this study is that the program for diagnosing a germline 
mutation in the BRCA1/2 genes and for preventative strategies should be considered cost 
effective when its impact on family members of patients diagnosed with ovarian cancer is 
assessed. Different studies published in the literature have also shown the cost effectiveness 
of performing genetic tests and of risk-reducing surgical procedures.
One potential limitation of this study is the use of estimates and probabilities from 
international observational studies, since national data was unavailable. The use of billing 
information may also have caused distortions because of potential discrepancies regarding 
the cost of procedures. However, this perspective has the advantage of representing the 
actual payments made by the National Health Service in the federal domain.
Finally, the determination of the incremental cost-effectiveness ratio, even though it is very 
useful for informed decision-making, is not enough for the incorporation of technologies 
into the National Health System15. That decision can be influenced by many variables, 
such as political interest and priorities, social preferences, concerns about equity, financial 
availability, and budgetary impact. Thus, one possible ramification of this study would be 
the need to analyze the budgetary impact of turning the program into one of the country’s 
health policies. Although the technology is considered cost effective, it is essential to know 
how much money the program would cost if it were offered by the National Health System to 
the Brazilian population. Such an analysis could guide decision-making and public policies 
for conditions such as ovarian cancer, which are highly lethal and often diagnosed quite late.
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